Ileostomy - Stoma Clinical Trial
— INSIDEOfficial title:
Modulation of Small Intestinal Microbial Composition and Activity,Systemic Immune Adaptation and Blood Transcriptional Changes Induced by 2-wks Consumption With 2 Fermented Milk Products;a Randomized,Exploratory,Cross-over,Double Blind,Controlled Study in Ileostomy Patients
Verified date | July 2018 |
Source | Maastricht University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To determine the small intestinal microbiota response in humans to dietary interventions for two consecutive weeks, and to relate this to parameters of intestinal barrier function and immune and metabolic responses in blood, as functional outcome parameters of host physiology
Status | Completed |
Enrollment | 16 |
Est. completion date | November 11, 2017 |
Est. primary completion date | November 11, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - • Ileostomy installed at least 3 years prior to participation - Free of any complications originating from the colectomy procedure for at least 1 yr prior to participation, with the exception of possible skin irritation at the location of the stoma - BMI from 18 till 28 kg/m2 - Age from 18 till 70 years - Available for entire study protocol. - For female: If of child bearing potential, female subjects must be using or complying with methods of contraception (such as oral birth control pills, intra-uterine device, double barrier methods (like condoms and spermicide, etc.) Exclusion Criteria: - • History of cardiovascular, respiratory, urogenital, hepatic, haematological / immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological diseases, allergy, laboratory assessments which might limit participation in or completion of the study protocol, and/or major surgery with the exception of total colectomy, hysterectomy and/or appendectomy. - Subject with known lactose intolerance or with known or suspected allergy or hypersensitivity to any component of the study product(s) (milk protein for example) + sucrose + rhamnose - Severe gastrointestinal symptoms. In case of mild gastrointestinal symptoms, the principal investigator and the medically responsible MD will judge eligibility to participate. - Removal of more than 15 cm of the ileum during or at any moment after the colectomy procedure - Abdominal surgery interfering with gastrointestinal function, upon judgment of the principal investigator and the medically responsible MD - Use of medication, including proton pump inhibitors, non-steroidal anti-inflammatory drugs interfering with endpoints (but except oral contraceptives), within 14 days prior to and during participation. - Consumption of any probiotic or prebiotic supplements or pre- and probiotics containing food products, investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principal investigator), in the 4 weeks prior to the study and during study participation (E4 PreProbiotics). - Use of antibiotics in the 4 weeks prior to the start of study and during study participation - Prohibited use of pro-, pre- or synbiotics during study period and three months prior to start of study. A list with forbidden products will be provided` - History of any side effects towards intake of pro- or prebiotic supplements of any kind. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Maastricht University Medical Centre | Maastricht | Limburg |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Temporal microbial composition and activity in the small intestine in ileal effluent | The microbiome activity will be determined as a function of the diet by double strand cDNA production and random sequencing of mRNA enriched fractions of total effluent RNA obtained from the effluent samples at the start and end of each intervention period. | 2 weeks intervention | |
Secondary | Small intestinal permeability by a multi sugar test (urinary recovery of test sugars) | 2 weeks intervention | ||
Secondary | Gene transcription response in blood by transcriptome patterns. | Transcriptome patterns will be determined in peripheral blood mononuclear cells obtained from blood samples from the participating ileostoma patients | 2 weeks intervention | |
Secondary | The levels of a panel of peripheral blood biomarkers related to immune, metabolic and hormonal status | A panel of biomarkers will be determined in peripheral blood obtained at the start and end of the intervention periods | 2 weeks intervention | |
Secondary | The level of whole blood immune responsiveness to a panel of standardized stimuli ex vivo | Peripheral whole blood immune responsiveness towards a subset of bacterial immune-stimuli will be assessed using the standardized truculture system | 2 weeks intervention | |
Secondary | Morning urine metabolome profiles | The principal analytical methodology employed is mass-spectrometry profiling and can commonly provide reliable quantifications of more than 400 named-metabolites in different body-fluid samples. | 2 weeks intervention | |
Secondary | Peripheral blood metabolome profiles | The principal analytical methodology employed is mass-spectrometry profiling and can commonly provide reliable quantifications of more than 400 named-metabolites in different body-fluid samples. | 2 weeks intervention | |
Secondary | The relative survival of bacterial strains (colony forming unit enumeration on semi-selective culture plates) | 2 weeks intervention | ||
Secondary | Short chain fatty acid profiles in ileal effluent | 2 weeks intervention | ||
Secondary | Number of participants with Gastrointestinal symptoms by Visual Analogue Scales | 2 weeks intervention | ||
Secondary | Occurrence and severity of treatment related adverse events | 2 weeks intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03746353 -
Early Closure Versus Conventional Closure in Postoperative Patients With Low Anteriresection for Rectal Cancer
|
N/A | |
Completed |
NCT03331783 -
Assessment of the Effect of Output on New Adhesives
|
N/A | |
Completed |
NCT02886455 -
Evaluation of the Influence of Output on Skin Covered by Newly Developed Adhesives
|
N/A | |
Completed |
NCT02517541 -
A Clinical Investigation Evaluating and Understanding Parameters Affecting the Performance of Ostomy Products
|
N/A | |
Completed |
NCT01939600 -
Digestibility of Selected Resistant Starches in Humans
|
N/A | |
Completed |
NCT01957553 -
Investigating the Safety and Performance of a New 2-piece Ostomy Product Compared With SenSura Click 2-piece
|
N/A | |
Terminated |
NCT01994863 -
Safety and Performance Investigation of a New 1-piece Ostomy Product Compared to Standard of Care 1-piece in Subjects With Ileostomy
|
Phase 2 | |
Completed |
NCT01994876 -
Investigation of Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy
|
N/A | |
Completed |
NCT03289013 -
Assessement of the Peal Force Needed to Peel New Adhesives From the Skin
|
N/A | |
Terminated |
NCT03416023 -
Safety, Performance and Durability of the TIES® Implant in Patients Requiring a Permanent Ileostomy
|
N/A | |
Completed |
NCT02997267 -
Early Closure of Protective Ileostomy in Rectal Cancer Patients
|
N/A | |
Recruiting |
NCT01880918 -
A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing
|
N/A | |
Completed |
NCT01957397 -
Investigation of Three Newly Developed 2-piece Convex Base-plates in Subjects With Ileostomy
|
N/A | |
Recruiting |
NCT04577456 -
Chyme Reinfusion for Type 2 Intestinal Failure
|
N/A | |
Terminated |
NCT03587519 -
Short Versus Long Interval to Ileostomy Reversal After Ileal Pouch Surgery
|
N/A | |
Recruiting |
NCT03872271 -
Is Diverting Loop Ileostomy Necessary in Completion Proctectomy With Ileal Pouch Anal- Anastomosis: A Multicentre, Randomized Study of the GETAID Chirurgie Group. IDEAL Trial
|
N/A | |
Completed |
NCT04606004 -
Perianal Maceration in Pediatric Ostomy Closure Patients
|
N/A | |
Completed |
NCT02886403 -
Evaluation of the Influence of Output on a Newly Develop Adhesive
|
N/A | |
Recruiting |
NCT03424447 -
Stimulation of the Efferent Loop Before Loop Ileostomy Closure
|
Phase 2 | |
Completed |
NCT03770078 -
Assessment of New Enhanced Ostomy Device in Real-life Settings in Subjects Having a Stoma
|
N/A |